Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.

Neurobiology of disease - 1 Feb 2011

Chou An-Hsun, Chen Si-Ying, Yeh Tu-Hsueh, Weng Yi-Hsin, Wang Hung-Li

Abstract excerpt

Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disease caused by polyglutamine-expanded ataxin-3. Previously, we prepared a SCA3 animal model by generating transgenic mice expressing disease-causing ataxin-3-Q79. Mutant ataxin-3-Q79 caused cerebellar malfunction o...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Ataxin-1
Share to Ataxin-3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ataxins

Share to Butyric Acid

Share to Enzyme Inhibitors

Share to Histone Deacetylases

Share to Machado-Joseph Disease

Source

Identifiers

PMID: 21047555
DOI: 10.1016/j.nbd.2010.10.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21047555-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.PMID 21047555Read ↗

Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4.Semantic proximity Read ↗

Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA.Semantic proximity Read ↗

A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.Semantic proximity Read ↗

Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.Semantic proximity Read ↗

A novel Ataxin-3 knock-in mouse model mimics the human SCA3 disease phenotype including neuropathological, behavioral, and transcriptional abnormalitiesSemantic proximity Read ↗

Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3Semantic proximity Read ↗

Naa10 regulates hippocampal neurite outgrowth <i>via</i> Btbd3 N-α-acetylation-mediated actin dynamicsSemantic proximity Read ↗

Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.Semantic proximity Read ↗

Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damageSemantic proximity Read ↗

H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse.Semantic proximity Read ↗

Epigenetic regulation of the human ATP2A3 gene promoter in gastric and colon cancer cell linesSemantic proximity Read ↗

A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.